Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as triamcinolone acetonide (Triesence®)
triamcinolone acetonide · 1 trial · 5 indications
Intraocular pressure is the fluid pressure inside the eye. Intraocular pressure change from baseline at week 8 was measured by Goldmann applanation tonometry. Tonometry is the method eye care professionals use to determine this pressure. Intraocular pressure is typically measured in millimeters of mercury. A higher pressure inside the eye can be a risk factor for developing glaucoma or glaucoma progression leading to optic nerve damage. A negative change indicates a reduction in intraocular pressure.
Visual acuity (VA) rates a person's ability to recognize small details with precision. Best corrected VA refers to this measurement when the best vision has be achieved following refraction. Visual acuity change from baseline at 8 and 26 weeks was measured following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol using standardized lighting and lanes and an ETDRS eye chart. This eye chart comprises rows of letters, with 5 letters per row, and with the letter size from line to line varying logarithmically and is used to estimate visual acuity. Visual acuity is scored with reference to the logarithm of the minimum angle of resolution or logMAR. Zero logMAR indicates standard vision, positive values indicate poor vision and negative values indicate good vision. A negative changes indicates an improvement in visual acuity.
| Arm | Type | Description |
|---|---|---|
| triamcinolone acetonide (Triesence®) | EXPERIMENTAL | TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS) |
| Name | Type | Description |
|---|---|---|
| triamcinolone acetonide (Triesence®) | DRUG | 4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space |
Inclusion Criteria: * diagnosis of non-infectious intermediate, posterior or pan-uveitis Exclusion Criteria: * any ocular trauma within the past 6 months in the study eye * any injection of intraocular corticosteroids or steroid implant or the Ozurdex® implant in the 6 months prior to the study t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Roivant Sciences Ltd. | ROIV | 1 | PHASE3 | Brepocitinib |
| Eli Lilly and Company | LLY | 1 | PHASE3 | Baricitinib, Adalimumab |
| ANI Pharmaceuticals, Inc. | ANIP | 1 | PHASE3 | Yutiq Drug |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |